Olanrewaju Esan, MD
Pulmonary Disease · W Hempstead, NYNPI 1861494239
Payments from drug & device makers
Across 465 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Amgen$561
- Boehringer Ingelheim$498
- Mylan Specialty L.p.$455
- plus $3K from 29 others
What the payments were for
- Food & beverage$10,07995%
- Education$5365%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 120 | $2,316 |
| AstraZeneca | 86 | $1,879 |
| Regeneron Healthcare Solutions, Inc. | 53 | $1,415 |
| Amgen | 26 | $561 |
| Boehringer Ingelheim | 23 | $498 |
| Mylan Specialty L.p. | 25 | $455 |
| Philips North America LLC | 19 | $429 |
| Baxter Healthcare | 15 | $302 |
| United Therapeutics Corporation | 6 | $287 |
| Sanofi | 10 | $229 |
| Viatris Specialty LLC | 8 | $227 |
| Genentech USA, Inc. | 8 | $193 |
| Verona Pharma, Inc. | 7 | $180 |
| Jazz Pharmaceuticals Inc. | 8 | $167 |
| Sanofi-aventis U.S. LLC | 2 | $164 |
| Electromed, Inc. | 6 | $153 |
| Actelion Pharmaceuticals US, Inc. | 3 | $150 |
| Chiesi USA, Inc. | 1 | $132 |
| Advanced Respiratory, Inc | 6 | $129 |
| Johnson & Johnson | 2 | $124 |
| Insmed, Inc. | 6 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 2 | $70 |
| Phadia US Inc. | 3 | $62 |
| Novartis | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Merck | 2 | $33 |
| Inogen, Inc. | 2 | $32 |
| ZOLL Respicardia, Inc. | 2 | $29 |
| 3b Medical, Inc. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Circassia Inc. | 1 | $17 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,615 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 453 | $461,712 |
| Dupixent PenDupilumab | 26 | $113,040 |
| NucalaMepolizumab | 17 | $98,608 |
| Fasenra PenBenralizumab | 11 | $61,215 |
| Breo ElliptaFluticasone/Vilanterol | 109 | $54,313 |
| Dupixent SyringeDupilumab | 12 | $52,358 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $40,609 |
| Spiriva RespimatTiotropium Bromide | 36 | $34,154 |
| Arnuity ElliptaFluticasone Furoate | 77 | $26,552 |
| Incruse ElliptaUmeclidinium Bromide | 44 | $23,228 |
| Theophylline ErTheophylline Anhydrous | 325 | $16,167 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $11,353 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $9,661 |
| XareltoRivaroxaban | 12 | $9,526 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $7,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,316 | $674,075717 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,879 | $51,96279 claims |
| Boehringer IngelheimSpiriva Respimat | $498 | $34,15436 claims |
| Johnson & JohnsonXarelto | $124 | $9,52612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in W Hempstead
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.